Clerio Vision is developing a non-invasive, tissue-sparing laser technology that corrects vision by modifying the reactive index of the cornea. It’s the third med-tech spinout from the University of Rochester for CEO Mikael Totterman and is starting to get some press, including this BioTuesdays piece. I’m on the company’s board of directors.
I caught up with Mikael recently to discuss the company’s progress.
- (0:20) Clerio is developing a laser technology for refractive eye surgery. We already have LASIK. Do we need another approach?
- (2:44) So LASIK has downsides, but you also use lasers. What’s the difference?
- (3:35) How do you test something like this? What testing has been done?
- (4:51) If the technology is so promising, why did Bausch & Lomb stop development?
- (6:30) What steps have you taken with the company since its founding?
- (7:55) When can we expect to see a product on the market?
- (8:56) This is at least the third company you’ve spun out of U of R. What is the biggest lesson that you learned and how are you applying these insights to Clerio?
- (11:00) What sort of development costs are required for commercialization? How are you funded?
- (12:08) What else should I know?
- (13:25) When you make modifications to intraocular lenses for cataracts, do you do it before or after implantation?